Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLS006 in Cutaneous Common Warts
NCT02971891Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Jan 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of furosemide in common warts (2 arms), sponsored by Maruho Co., Ltd. Primary endpoint: Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at 18 weeks. Started Jan 2017; status: completed.
02
Drugs
furosemide
03
Conditions
common warts
Beyond the preview
Go deeper on NCT02971891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971891.